Literature DB >> 33738055

Tumor-Targeted Bivalent Protein Degradation for Application in Cancer Therapy.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2021        PMID： 33738055      PMCID： PMC7957931          DOI： 10.1021/acsmedchemlett.1c00084

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Bromodomains: a new target class for drug development.

Authors:  Andrea G Cochran; Andrew R Conery; Robert J Sims
Journal:  Nat Rev Drug Discov       Date:  2019-07-04       Impact factor: 84.694

Review 2.  Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.

Authors:  Dailin Liang; Yifan Yu; Zonghui Ma
Journal:  Eur J Med Chem       Date:  2020-05-11       Impact factor: 6.514

Review 3.  How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?

Authors:  C Mary Schooling; Jie V Zhao
Journal:  Am J Cardiovasc Drugs       Date:  2019-04       Impact factor: 3.571

Review 4.  A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II-Biological functions and inhibitors.

Authors:  Jianru Zhang; Xiaoyun Zhang; Huidan Huang; Yimei Ding
Journal:  Bioorg Chem       Date:  2020-09-28       Impact factor: 5.275

Review 5.  Chemical Epigenetics: The Impact of Chemical and Chemical Biology Techniques on Bromodomain Target Validation.

Authors:  Matthias Schiedel; Mustafa Moroglu; David M H Ascough; Anna E R Chamberlain; Jos J A G Kamps; Angelina R Sekirnik; Stuart J Conway
Journal:  Angew Chem Int Ed Engl       Date:  2019-11-14       Impact factor: 15.336

Review 6.  Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.

Authors:  Ewelina Kulikowski; Brooke D Rakai; Norman C W Wong
Journal:  Med Res Rev       Date:  2020-09-14       Impact factor: 12.944
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.